Moberg Pharma Completes Divestment of PediaCare for $5.6 Million

STOCKHOLM, Sweden, Dec 20, 2016 /PRNewswire/ --

Moberg Pharma AB (OMX: MOB) announces that the company has completed the divestment of the PediaCare® brand to Strides Arcolab International Limited, UK for a total consideration of $5.6 million, whereof $0.6 million comprises inventory value.

Moberg Pharma's strategy is to build value through profitable growth of strategic brands, to increase the value of pipeline assets and to make value-adding acquisitions.

Divesting PediaCare® enables Moberg Pharma to focus on its core business. The divested brand originated from an acquisition in July 2016 where the primary purpose was to acquire New Skin® - a strategic asset in specialty skin care. The divestment of PediaCare® results in no capital gain or loss.

Advisors

Hansen Law was engaged as legal advisor for the divestment of PediaCare®.

About this information

This information is information that Moberg Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8.30 a.m. CET on December 20th, 2016. 

CONTACT:

For additional information, please contact:

Peter Wolpert, CEO,
Phone: +46 707 35 71 35,
E-mail: peter.wolpert@mobergpharma.se

Anna Ljung, CFO,
Phone: +46 707 66 60 30,
E-mail: anna.ljung@mobergpharma.se

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/moberg-pharma/r/moberg-pharma-completes-divestment-of-pediacare-for--5-6-million,c2151976

The following files are available for download: